>
After the EU MDR transition period was recently extended, it quickly became clear that the extension doesn't mean that all medtech companies can delay compliance for all devices. Which companies will benefit the most and which devices will need to comply with MDR more quickly? How will the "sell-off" period removal affect the industry and what happens now that the MDR transition period extends beyond the expected start of mandated EUDAMED compliance? Our expert panel, including Rimsys Founder and President, James Gianoutsos; Bruce McKean, Director of Regulatory with Rimsys; and Adam Price, Director of Product with Rimsys answered a lot of questions!
More infoWatch ReplayGet the ebookGet the briefGet the case studyGet the data sheetGet the webinarGet the video